On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE (NASDAQ:BNTX).The data were presented in an oral session at the 2024 European Society of Medical Oncology Asia Annual Meeting in Singapore and showed encouraging antitumor activity alongside a manageable safety profile in heavily pretreated patients with locally advanced or metastatic solid tumors.The ongoing Phase 1/2a trial analysis included 277 participants across various solid tumor types.Also Read: BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus AcquisitionThe trial’s primary endpoints are safety and an objective response rate. The secondary endpoints include duration of response, disease control rate, progression-free survival, and overall survival.The data showed the following results: ...Full story available on Benzinga.com